Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 03

827P - An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker results

Date

10 Sep 2022

Session

Poster session 03

Topics

Clinical Research;  Immunotherapy

Tumour Site

Presenters

Kevin Harrington

Citation

Annals of Oncology (2022) 33 (suppl_7): S356-S409. 10.1016/annonc/annonc1059

Authors

K.J. Harrington1, J.J. Sacco2, A. Olsson-Brown3, T. Chan4, P. Nenclares1, I. Leslie1, P. Bommareddy5, C. Ahlers6, J. Wolff6, M.R. Middleton7

Author affiliations

  • 1 Dept. Of Radiotherapy And Imaging, ICR - Institute of Cancer Research - Chester Beatty Laboratories, SW3 6JB - London/GB
  • 2 Medical Oncology Department, Clatterbridge Cancer Center - NHS Foundation Trust, CH63 4JY - Wirral/GB
  • 3 Medical Oncology, The Clatterbridge Cancer Centre - Liverpool, L7 8YA - Liverpool/GB
  • 4 Interventional Radiology, Royal Liverpool University Hospital, L7 8XP - Liverpool/GB
  • 5 Translational, Replimune Inc., 01801 - Woburn/US
  • 6 Clinical Development, Replimune Inc., 01801 - Woburn/US
  • 7 Oncology Department, Churchill Hospital, OX3 7LE - Oxford/GB
More

Abstract 827P

Background

RP2 is an enhanced potency oncolytic herpes simplex virus (HSV) -1 expressing GM-CSF, a fusogenic protein (GALV-GP R-), and an anti-CTLA-4 antibody-like molecule that is being evaluated in an open-label, multicenter, phase 1 clinical trial as monotherapy and combined with nivolumab (nivo). Here, we present updated safety, efficacy, and biomarker data of RP2 ± nivo.

Methods

After determination of the RP2D (106 PFU/mL intratumorally (IT) once followed by up to 7 additional doses of 107 PFU/mL via IT), a cohort of 30 patients (pts) was enrolled and treated with RP2 combined with nivo (240 mg Q2W for 4 months from the second RP2 dose, then 480 mg Q4W for 20 months). Responses were assessed using modified RECIST v1.1.

Results

Objective responses with RP2 monotherapy were observed in 3 out of 9 pts including 1 CR for ≥15 months in mucoepidermoid carcinoma, 1 PR for ≥18 months in esophageal cancer with liver metastases, 1 PR in uveal melanoma with liver metastases that progressed at 15 months. Objective responses with RP2 + nivo treatment were 44.4% in cutaneous melanoma (4/9), 25% in uveal melanoma (2/8), and 33% in SCCHN (1/3) pts. All seven responding patients had previously failed anti-PD-1 therapy, with all but one response durable to date for >425 days. The most common adverse events (grade 1-2) were pyrexia, chills, influenza-like illness, fatigue, and pruritus. No grade 4-5 events were observed. Immunohistochemistry (IHC) analysis indicated robust increases in CD8 T cell influx, PD-L1 expression, and an increase in the CD8/foxp3+ cell ratio. Clinical responses were independent of baseline CD8 T cell infiltration, PD-L1 expression levels, and prior anti-PD-1 therapy status.

Conclusions

RP2 ± nivo demonstrated good tolerability and durable systemic responses in pts with difficult-to-treat, heavily pretreated and anti-PD-1 failed advanced cancers. These data continue to support the hypothesis that oncolytic delivery of anti-CTLA-4 into tumors, with accompanying antigen release, presentation and immune activation, can provide potent systemic anti-tumor effects.

Clinical trial identification

NCT04336241.

Editorial acknowledgement

Legal entity responsible for the study

Replimune Inc.

Funding

Replimune Inc.

Disclosure

K.J. Harrington: Financial Interests, Institutional, Advisory Board: Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Merck, MSD, Pfizer, Replimune, Oncolys, Vyriad, Idera; Financial Interests, Institutional, Other, Honoraria for lectures: Amgen, AstraZeneca, BMS, Boehringer Ingelheim; Financial Interests, Institutional, Advisory Board, Advisory board for CD47 assets: Arch Oncology; Financial Interests, Institutional, Advisory Board, Development of DDR assets: ARTIOS; Financial Interests, Institutional, Advisory Board, Development of exosomal STING agonist: Codiak; Financial Interests, Institutional, Advisory Board, Development of oncolytic adenovirus: PsiVac; Financial Interests, Institutional, Funding, Research: AstraZeneca, Boehringer Ingelheim, MSD; Financial Interests, Institutional, Funding, Development of oncolytic HSV platform: Replimune; Non-Financial Interests, Leadership Role, Chair of Steering Committee: ART NET; Non-Financial Interests, Other, Member of Global Steering Committee: MR - Linac. J.J. Sacco: Financial Interests, Institutional, Principal Investigator: Replimune Inc ; Financial Interests, Institutional, Sponsor/Funding: AstraZeneca, BMS, Immunocore; Financial Interests, Personal, Invited Speaker: Pierre- Fabre, BMS. P. Bommareddy: Financial Interests, Personal, Stocks/Shares: Replimune Inc . C. Ahlers: Financial Interests, Personal, Stocks/Shares: Replimune Inc . J. Wolff: Financial Interests, Personal, Stocks/Shares: Replimune Inc . M.R. Middleton: Financial Interests, Personal, Advisory Board, Advice on drug development and clinical trial design: Alkermes, Kineta, Silicon Therapeutics, Immunocore, Replimune; Financial Interests, Personal, Advisory Board, Advice on patient experience measures and research design: BMS; Financial Interests, Institutional, Invited Speaker, Fees for clinical trial conduct: Replimune; Financial Interests, Institutional, Invited Speaker, Fees for trial conduct: BMS, Alkermes, GSK, Merck KGa, MSD, Pfizer, Regeneron, Bioline, Novartis, Roche, Medivir; Financial Interests, Institutional, Funding, Educational grant towards IIS; fees for clinical trial conduct: Immunocore; Financial Interests, Institutional, Invited Speaker, Grant towards IIS: GRAIL; Non-Financial Interests, Other, Multiple roles as reviewer and committee member: Cancer Research UK; Non-Financial Interests, Member: AACR, ASCO, ACP. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.